Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Board OKs Safeguard to Protect Investors Against Abusive Tactics, Including Takeover

NEW YORK, July 14 (GenomeWeb News) - The board of directors of Alnylam Pharmaceuticals has approved a rights agreement to ensure that its stockholders receive preferred stock purchase rights in case of certain 'abusive tactics,' the Cambridge, Mass.-based RNAi company said today.

 

The amendment specifically states it will protect "the long-term value of the stockholders' investment" in the event of a takeover or other actions that could affect the ownership or leadership of the company, according to Alnylam.

 

"The board believes the rights agreement is a prudent measure to safeguard the interests of our stockholders so that they receive fair and equal treatment in the event of any proposed takeover of Alnylam and to guard against partial tender offers, squeeze-outs and other abusive tactics to gain control of Alnylam that could impair the board's ability to represent stockholders' interests fully," Alnylam president and CEO John Maraganore said in a statement.

 

More information about the rights agreement can be found here.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.